World’s First Phase III Positive B7-H3 ADC: Medicilon Congratulates MediLink Therapeutics on NDA Acceptance of Icontamrotamab

On July 18, China’s Center for Drug Evaluation (CDE) accepted the New Drug Application (NDA) for icontamrotamab for injection (Tam-Peli, YL201), a B7-H3-targeted ADC independently developed by MediLink Therapeutics. As the world’s first B7-H3 ADC with positive Phase III results, YL201 has officially entered its launch phase, offering a promising new treatment option for patients […]